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In Brief
MCL-1 is overexpressed in various
human cancers. Grabow et al. reveal the
importance of MCL-1 for the survival of B
cell progenitors undergoing neoplastic
transformation and in lymphomagenesis.
Given that non-transformed cells appear
to be less dependent on MCL-1 than
malignant ones, inhibitors of MCL-1 may
be useful in cancer therapy.
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MCL-1 is critical for progenitor cell survival during
emergency hematopoiesis, but its role in sustaining
cells undergoing transformation and in lymphoma-
genesis is only poorly understood. We investi-
gated the importance of MCL-1 in the survival of B
lymphoid progenitors undergoing MYC-driven trans-
formation and its functional interactions with pro-
apoptotic BIM and PUMA and the tumor suppressor
p53 in lymphoma development. Loss of one Mcl-1
allele almost abrogated MYC-driven-lymphoma de-
velopment owing to a reduction in lymphoma initi-
ating pre-B cells. Although loss of the p53 target
PUMA had minor impact, loss of one p53 allele sub-
stantially accelerated lymphoma development when
MCL-1 was limiting, most likely because p53 loss
also causes defects in non-apoptotic tumor suppres-
sive processes. Remarkably, loss of BIM restored the
survival of lymphoma initiating cells and rate of tumor
development. Thus, MCL-1 has a major role in lym-
phoma initiating pro-B cells to oppose BIM, which
is upregulated in response to oncogenic stress.
INTRODUCTION
Cells must acquire several attributes to undergo neoplastic
transformation (Hanahan and Weinberg, 2011). This is driven
by the activation of oncogenes, such as deregulation of MYC
expression, and loss of function of tumor suppressor genes,
such as mutations in p53. Many oncogenic lesions (e.g., deregu-
lated MYC expression) drive aberrant proliferation and therefore
impose a stress on nascent tumor cells that can trigger tumor
suppressive processes, such as apoptosis (Delbridge et al.,
2012). Accordingly, inhibition of apoptosis is required to facilitate
survival of cells undergoing neoplastic transformation. Interest-
ingly, somatically acquired gene copy-number amplifications
of the pro-survival BCL-2 family members MCL1 (Myeloid Cell
Leukemia-1, mouse homolog described in this study is calledCellMcl-1) and BCL-X (or BCL2L1; BCL-2-like 1; mouse homolog
described in this study is called Bcl-x) are found in many human
cancers (Beroukhim et al., 2010).
The importance of maintaining sufficient MCL-1 protein levels
to sustain enhanced cell proliferation was recently demonstrated
when loss of a single allele of Mcl-1 was shown to severely
compromise the survival of proliferating hematopoietic progeni-
tor cells, resulting in the failure to reconstitute a functional he-
matopoietic system in Mcl-1+/ mice exposed to 5-fluorouracil
(5-FU) or g-irradiation (Delbridge et al., 2015b).
Activation of oncogenes, such as MYC, causes not only
enhanced proliferation but also replicative stress with concomi-
tant DNA damage (Soucek and Evan, 2010). These stress stimuli
activate the key tumor suppressor p53 (protein 53 kDa), which
orchestrates downstream pathways to elicit cell-cycle arrest
via p21 (protein 21 kDa, also known as cyclin-dependent kinase
inhibitor 1 [CDKN1] or CDK-interacting protein 1 [Cip1] or Waf1)
and/or apoptosis through PUMA (p53 upregulated modulator of
apoptosis; official name of the mouse gene: Bbc3; here we used
Puma) and NOXA (official gene name: Pmaip1; Phorbol-12-myr-
istate-13-acetate-induced protein 1) (Oda et al., 2000; Nakano
and Vousden, 2001; Valente et al., 2015). Defects in the p53
pathway cooperate with deregulated MYC expression in tumor-
igenesis. Strikingly, 70% of human cancers present with aber-
rant MYC expression highlighting its importance in tumor devel-
opment (Soucek and Evan, 2010). Interestingly, many of these
cancers also carry p53 pathway defects (Vousden and Lu, 2002).
Considerable insight into the impact of deregulated MYC
expression has come from the study of Em-Myc transgenic
mice in whichMYC overexpression is driven by the IgH enhancer
(Adams et al., 1985). This causes abnormally increased prolifer-
ation of B cell progenitors (Langdon et al., 1986), which upon
acquisition of cooperating oncogenic lesions progress to clonal
pre-B or sIg+ B cell lymphoma (Harris et al., 1988). It is still un-
known which pro-survival and pro-apoptotic proteins are essen-
tial for the sustained survival of B cell progenitors during
neoplastic transformation following oncogene activation and
what other pathways have to be deregulated to facilitate malig-
nant transformation. Since MCL-1 is critical for the survival of
proliferating hematopoietic stem and progenitor cells (Delbridge
et al., 2015b), we examined the impact of limiting MCL-1 proteinReports 14, 2337–2347, March 15, 2016 ª2016 The Authors 2337
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Figure 1. Loss of One Allele of Mcl-1 Substantially Reduces the Incidence and Greatly Delays the Onset of MYC-Driven Lymphoma
Development
(A) Kaplan-Meier curves showing lymphoma-free survival of Em-Myc;Mcl-1+/ and control Em-Myc mice (p < 0.0001; log-rank Mantel-Cox test).
(B and C) Leukemic cell counts in the blood (pblood = 0.64) (B) and spleen weights (pspleen = 0.25) (C) from sick Em-Myc;Mcl-1
+/ and control Em-Myc mice at
sacrifice. In (B) and (C), the color code for genotypes is the same as in (A); mouse numbers are indicated (n) and each dot represents a single mouse. Data are
presented as mean ± SEM.
(D) Histological analysis of bone marrow (sternum) and spleen specimens of sick mice of the indicated genotypes; representative examples given. Scale bar
denotes 200 mm.
(E) Western blot analysis of the indicated proteins (HSP70 = loading control) in lymphoma cells from mice of the indicated genotypes (representative of 9–16
lymphomas of each genotype).levels on the survival of abnormally proliferating B cell progeni-
tors that initiate lymphomagenesis in Em-Myc mice and the rate
of tumor development.
RESULTS
Loss of One Allele of Mcl-1 Substantially Delays
MYC-Driven Lymphoma Development
Expression from both alleles ofMcl-1 is essential for the survival
of hematopoietic stem and progenitor cells during stress-
induced repopulation of the hematopoietic system (Delbridge
et al., 2015b). Therefore, we hypothesized that a reduction in
MCL-1 protein levels might impede lymphoma development.
This question is of particular interest given the ongoing efforts
to develop MCL-1 inhibitors for anti-cancer therapy (Goodwin
et al., 2015; Leverson et al., 2015). Hence, we generated Em-
Myc;Mcl-1+/ mice to examine the impact of limiting levels of
MCL-1 on the survival of pre-leukemic B lymphoid cells undergo-
ing neoplastic transformation and on the rate of pre-B/B lym-
phoma development.
Em-Myc;Mcl-1+/ mice developed lymphoma with consider-
ably reduced incidence and much longer latency compared to2338 Cell Reports 14, 2337–2347, March 15, 2016 ª2016 The Authorcontrol Em-Mycmice (median survival: Em-Myc = 90 days versus
61% of Em-Myc;Mcl-1+/ lymphoma-free at 800 days; Mantel-
Cox log-rank test: p < 0.0001; Figure 1A). Remarkably, at the
time when almost all Em-Myc control mice had succumbed to
lymphoma (200 days), > 80% of Em-Myc;Mcl-1+/mice still re-
mained lymphoma-free.
The few Em-Myc;Mcl-1+/ mice that became sick presented
with a lymphoma burden similar to sick Em-Myc animals, as
shown by their lymphocyte counts in the blood (p = 0.6418; Fig-
ure 1B) and spleen weights (pspleen = 0.25; Figure 1C). The lymph
node weights were significantly lower in sick Em-Myc;Mcl-1+/
mice than sick Em-Mycmice (plymph nodes = 0.01), but the platelet
numbers were similar (pplatelets = 0.13; Figure S1). Histological
examination confirmed extensive accumulation of lymphoma
cells in the bone marrow and spleen of the sick Em-Myc;Mcl-
1+/ mice, and this was comparable to the lymphoma burden
seen in sick Em-Myc mice (Figure 1D). Flow cytometric analysis
revealed that Em-Myc;Mcl-1+/ mice developed mostly sIg+
B cell lymphoma (91%, B220+IgM+) and only rarely pre-B
lymphoma (9%, B220+sIg). Conversely, 57% of Em-Myc mice
developed sIg+ B lymphoma, 36% pre-B cell lymphoma, and
7% mixed pre-B/B lymphoma (Figure S2A). Western blots
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B C Figure 2. Loss of One Allele of Mcl-1 Sub-
stantially Reduces the Numbers of MYC-
Overexpressing Pre-leukemic B Lymphoid
Cells Undergoing Neoplastic Transformation
(A–C) Counts (per femur) of (A) pro-B cells
(B220+sIgc-KIT+), (B) pre-B cells (B220+sIgc-
KIT), and (C) sIg+ B cells (B220+sIg+c-KIT) in
the bone marrow of pre-leukemic Em-Myc and
Em-Myc;Mcl-1+/ mice as well as WT and Mcl-
1+/ mice at the age of 3–4 weeks (Em-Myc
versus Em-Myc;Mcl-1+/: ppro-B = 0.0754; ppre-B <
0.0001; psIg+-B = 0.0012; n = 4–6 mice for each
genotype).
(D–F) Survival in vitro in simple medium (10%
FBS but no added cytokines) of FACS sorted
(D) pro-B, (E) pre-B, and (F) sIg+ B cells of
the indicated genotypes was measured at the
indicated time points by flow cytometry (pro-B:
p24h = 0.0472 and 48 hr p48h = 0.0063, for
comparison between Em-Myc and Em-Myc;Mcl-
1+/). n = 4–6 mice for all genotypes. Data are
presented as mean ± SEM.analysis showed that despite the loss of one allele of Mcl-1, the
MCL-1 protein levels inmany Em-Myc;Mcl-1+/ lymphomaswere
comparable to those seen in lymphomas from Em-Mycmice (Fig-
ure 1E). This indicates compensatory upregulation of MCL-1
expression from the remaining wild-type (WT) Mcl-1 allele. We
did not observe consistent differences in the protein expression
of pro-survival BCL-2 and BCL-XL or pro-apoptotic BIM and
PUMA between Em-Myc;Mcl-1+/ and Em-Myc lymphomas (Fig-
ure 1E). To test whether expression from the remainingWTMcl-1
allele is upregulated in Em-Myc;Mcl-1+/ lymphomas, we per-
formed qRT-PCR analysis. We found thatMcl-1 transcript levels
were not significantly different between Em-Myc;Mcl-1+/ and
Em-Myc lymphomas, revealing that expression from the WT
Mcl-1 allele must indeed have been upregulated in the former
(Figure S2B).
Approximately 20%–30% of lymphomas arising in Em-Myc
mice harbor defects that disable the p53 pathway (Eischen
et al., 1999; Michalak et al., 2009). Western blot analysis for
p53 and p19ARF (high levels of these proteins indicate defects
in the p53 pathway) revealed that there was no significant
difference in the frequency of p53-pathway defects between
Em-Myc;Mcl-1+/ (38%; 6/16) versus Em-Myc (33%, 3/9) lym-
phomas (Figures 1E and S3). DNA sequence analysis failed to
detect mutations in p53 that affect its DNA binding regions (the
region where most mutations in p53 are found in cancers; exons
4–10) in any of the Em-Myc;Mcl-1+/ lymphomas (9 lymphomas
tested, versus 3 WT control cell samples). These results show
that loss of one Mcl-1 allele greatly delays MYC-induced lym-
phoma development and that this is not accompanied by an
increased selection for p53 pathway defects in the few lym-
phomas that arise in the Em-Myc;Mcl-1+/ mice.
Loss of One Allele of Mcl-1 Substantially Reduces
MYC-Driven Accumulation of Pre-leukemic Cancer
Initiating Cells
Since Em-Myc;Mcl-1+/ mice survived considerably longer than
their Em-Myc counterparts, we investigated the impact of loss
of one Mcl-1 allele on the accumulation of pre-leukemic BCelllymphoid progenitors, in which neoplastic transformation pro-
ceeds to produce malignant lymphomas (Harris et al., 1988).
At 4 weeks of age, Em-Myc mice showed no signs of malig-
nant disease, but as previously reported (Langdon et al., 1986),
they displayed a significant increase of leukocytes in the
blood (p = 0.0008; Figure S4A) and spleen (p = 0.046; Fig-
ure S4E) but not the lymph nodes (Figure S4F), compared to
WT mice. Em-Myc;Mcl-1+/ mice had markedly reduced over-
all leukocyte counts in these tissues compared to Em-Myc con-
trols (Em-Myc;Mcl-1+/ versus Em-Myc mice: pblood < 0.0001;
pspleen = 0.022, pLN = 0.055 [Figure S4]). In contrast, Mcl-1
+/
and WT mice had similar leukocyte counts in these tissues
(Figure S4A).
The blood of young Em-Myc;Mcl-1+/ mice had normal levels
of platelets, in contrast to the platelet reduction seen in
Em-Myc littermates (p = 0.011; Figure S4C). This is probably
due to the reduced stress on the bone marrow resident hemato-
poietic cells as a consequence of the reduced accumulation of
pre-leukemic cells, allowing normal platelet production. The
numbers of erythrocytes were comparable between mice of all
genotypes examined (Figure S4B).
Fluorescence-activated cell sorting (FACS) analysis revealed
that 3- to 4-week-old mice of all genotypes tested (i.e., in mice
with the Em-Myc transgene prior to appearance of malignant
lymphoma) contained comparable numbers of pro-B cells
(B220+c-KIT+sIg) (Figure 2A). As reported (Langdon et al.,
1986; Strasser et al., 1996), Em-Myc mice had increased
numbers of pre-B cells (B220+c-KITsIg) compared toWT con-
trols (p = 0.0003; Figure 2B). Interestingly, the numbers of the
pre-B cells and their progeny, the sIg+ B cells, were significantly
lower in Em-Myc;Mcl-1+/ mice compared to Em-Myc controls
(ppre-B < 0.0001 and psIg+-B = 0.0012; Figures 2B and 2C). In
contrast, the numbers of all B cell subsets examined were com-
parable between WT and Mcl-1+/ mice (Figures 2A–2C).
We compared the survival of FACS sorted pro-B, pre-B, and
sIg+ B cells in simple medium with no added cytokines to inves-
tigate at which differentiation stage loss of one Mcl-1 allele
caused increased predisposition to apoptosis in pre-leukemicReports 14, 2337–2347, March 15, 2016 ª2016 The Authors 2339
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Figure 3. Loss of One Allele of p53 Substantially Increases the Incidence and Accelerates the Rate of MYC-Driven Lymphoma Development
when MCL-1 Protein Levels Are Limiting
(A) Kaplan-Meier curves showing lymphoma-free survival of Em-Myc mice of the indicated genotypes (survival curves for Em-Myc and Em-Myc;Mcl-1+/ are
reproduced from Figure 1A for comparison; x axis is shortened from 800 to 250 days to aid comparison between mice of the different genotypes).
(B and C) Leukemic cell counts in the blood (B) and spleenweights (C) of sick Em-Mycmice of the indicated genotypes at sacrifice. In (B) and (C), the color code for
genotypes is the same as in (A), and each symbol represents an individual mouse. Data are presented as mean ± SEM.
(D) Histological analysis of bone marrow (sternum) and spleen specimens of sick mice of the indicated genotypes; representative examples are given. Scale bar
denotes 200 mm.
(E) Western blot analysis of the indicated proteins (HSP70 = loading control) in lymphoma cells from mice of indicated genotypes (representative of 6–16
lymphomas of each genotype).Em-Myc B lymphoid cells. Em-Myc;Mcl-1+/ pro-B cells died
significantly faster than Em-Myc pro-B cells (p24h = 0.047,
p48h = 0.006; Figure 2D), but no difference in survival was
observed between Em-Myc;Mcl-1+/ versus Em-Myc pre-B or
sIg+ B cells (Figures 2E and 2F). All B lymphoid subsets tested
from WT andMcl-1+/mice showed comparable survival in cul-
ture (Figures 2D–2F). These results reveal that MCL-1 levels are
limiting for the survival of MYC-overexpressing, but not normal,
pro-B cells and that this causes a reduction in pre-leukemic
pre-B and sIg+ B cells in Em-Myc;Mcl-1+/ mice.
Loss of One Allele of p53 Greatly Accelerates
MYC-Driven LymphomaDevelopment EvenwhenMCL-1
Protein Levels Are Limiting
The tumor suppressor p53 is activated by replication stress and
DNA lesions and therefore imposes a critical barrier against
MYC-induced pre-B/B cell lymphoma development (Eischen
et al., 1999; Michalak et al., 2009). Loss of p53 function pre-
cludes PUMA and NOXA induced apoptosis triggered by DNA
damage, but also results in impaired DNA repair. This facilitates
accumulation of additional oncogenic mutations that can drive
neoplastic transformation. Accordingly, loss of one allele of2340 Cell Reports 14, 2337–2347, March 15, 2016 ª2016 The Authorp53 greatly accelerates MYC-driven lymphoma development
(Eischen et al., 1999; Michalak et al., 2009). We generated
Em-Myc;Mcl-1+/;p53+/ mice to examine whether defects in
the p53-pathway could overcome the delay in MYC-driven lym-
phoma development imposed by loss of one allele of Mcl-1.
Consistent with previous findings (Eischen et al., 1999; Micha-
lak et al., 2009), loss of one allele of p53 significantly acceler-
ated MYC-driven lymphoma development (median survival:
Em-Myc = 90 days, Em-Myc;p53+/ = 30 days, p < 0.0001; Fig-
ure 3A). Interestingly, Em-Myc;Mcl-1+/;p53+/ mice exhibited a
median survival of 41 days. Although their survival is significantly
(p < 0.0001) longer compared to Em-Myc;p53+/mice, this delay
in lymphoma onset is substantially less when comparing median
survival between Em-Myc;Mcl-1+/ and Em-Myc mice (Figures 1
and 3A). Sick Em-Myc;Mcl-1+/;p53+/ mice had significantly
(p = 0.017) fewer lymphoma cells in their blood than sick
Em-Myc;p53+/ mice; indeed the levels in the former were even
below the average leukemic cell counts in the blood of sick
Em-Myc mice (p = 0.023; Figure 3B). The spleen weights of
sick Em-Myc;Mcl-1+/;p53+/ mice were not significantly
different from those of sick Em-Myc;p53+/ mice (Figure 3C).
Moreover, the spleen and lymph node weights of Em-Myc;p53+/s
and Em-Myc;Mcl-1+/;p53+/ were not significantly different
from those of Em-Myc;Mcl-1+/ mice (Figures 3C and S5A).
This is probably due to the fact that Em-Myc;Mcl-1+/ mice
become sick at a much older age and therefore have consider-
ably higher body weights than the Em-Myc;p53 compound
mutant mice, which develop lymphoma before they are fully
grown. Histological analysis revealed similar accumulation of
lymphoma cells in the bone marrow and spleen in mice of all
genotypes (Figure 3D). Although the leukemic cell counts were
lower in the blood of sick Em-Myc;Mcl-1+/;p53+/ mice than
sick Em-Myc;p53+/ mice, the platelet counts were reduced to
a similar extent in both strains (Figure S5A). This indicates that
in Em-Myc mice of all genotypes the lymphoma burden in the
bone marrow sufficed to impair platelet production.
Western blot analysis revealed that many Em-Myc;Mcl-
1+/;p53+/ lymphomas expressed lower levels of MCL-1 and
in some cases also lower levels of BIM than the lymphomas
from Em-Myc mice, but the levels of these proteins were mostly
similar to those seen in Em-Myc;Mcl-1+/ lymphomas (Figures
3E and S3). Thus, in contrast to the Em-Myc;Mcl-1+/ lym-
phomas, at least some Em-Myc;Mcl-1+/;p53+/ lymphomas
may have undergone selection for reduced expression of BIM
rather than a compensatory increase in MCL-1 production
from the WT Mcl-1 allele. Collectively, these results show that
loss of one allele of p53 can greatly accelerate MYC-driven lym-
phomagenesis even when one Mcl-1 allele has been deleted.
Loss of Pro-apoptotic PUMA Accelerates Lymphoma
Development in Em-Myc;Mcl-1+/Mice Only to a Limited
Extent
PUMA is essential for p53-induced apoptosis (Jeffers et al., 2003;
Villunger et al., 2003) and binds with high affinity to MCL-1 (Chen
et al., 2005; Kuwana et al., 2005). In rapidly proliferating hemato-
poietic stem and progenitor cells, PUMA is the key mediator of
replicative stress induced apoptosis, particularly when MCL-1
levels are limiting (Yu et al., 2010; Delbridge et al., 2015b). Loss
of PUMA profoundly accelerates lymphoma development in
Em-Myc mice, albeit to a much lesser extent than loss of even
onep53 allele (Garrison et al., 2008;Michalak et al., 2009; Valente
et al., 2015). This demonstrates that p53 must suppress MYC-
driven lymphomagenesis through processes in addition to induc-
tion of apoptosis. Since Em-Myc;Mcl-1+/;p53+/ mice develop
lymphoma much more rapidly than Em-Myc;Mcl-1+/ mice, we
examined howmuch loss of PUMA-mediated apoptosis contrib-
utes to the tumor-promoting impact of loss of p53.
Consistentwithprevious reports (Garrisonet al., 2008;Michalak
et al., 2009), Em-Myc;Puma+/ and Em-Myc;Puma/mice devel-
oped lymphoma more rapidly than control Em-Mycmice (median
survival: Em-Myc = 90 days; Em-Myc;Puma+/ = 74 days,
p = 0.015 versus Em-Myc; Em-Myc;Puma/ = 62 days, p <
0.0001 versus Em-Myc; Figure 4A). Interestingly, only loss of
both alleles, but not loss of one allele, of Puma significantly
increased the incidence and accelerated the onset of lym-
phoma in Em-Myc;Mcl-1+/ mice (median survival: Em-Myc;Mcl-
1+/;Puma+/ = 516 days, p = 0.62; Em-Myc;Mcl-1+/;Puma/ =
260 days, p = 0.0037; Figure 4A).
Blood lymphocyte numbers in sick Em-Myc;Mcl-1+/, Em-
Myc;Mcl-1+/;Puma+/, and Em-Myc;Mcl-1+/;Puma/ miceCellwere comparable but all were significantly lower than those
seen in Em-Myc;Puma/ mice (p = 0.0151, p < 0.0001, p <
0.0001, respectively; Figure 4B). The spleen and lymph node
weights were significantly lower in sick Em-Myc;Mcl-1+/;
Puma+/ mice (pspleen < 0.0001; pLN = 0.0020) than sick Em-
Myc;Puma+/ animals, but only the spleen weights differed
between sick Em-Myc;Mcl-1+/;Puma/ and Em-Myc;Puma/
mice (pspleen < 0.0001; pLN = 0.43) (Figures 4C and S5B). Platelet
numbers were significantly higher in sick Em-Myc;Mcl-
1+/;Puma+/ and Em-Myc;Mcl-1+/;Puma/ mice than sick
Em-Myc;Puma+/ or Em-Myc;Puma/ animals, respectively
(ppuma+/ = 0.0003; ppuma/ < 0.0001; Figure S5B). This
indicates that the stress imposed by the lymphoma burden
was lower in the former. Histological and blood analyses re-
vealed that although some Em-Myc;Mcl-1+/;Puma+/ and Em-
Myc;Mcl-1+/;Puma/ mice had relatively low leukemic cell
counts in the blood, they still had extensive lymphoma burden
in the bone marrow, spleen, and lymph nodes (Figure 4D).
FACS analysis demonstrated that 29% of Em-Myc;Puma+/
and 40% of Em-Myc;Mcl-1+/;Puma/ lymphomas displayed
a pre-B cell phenotype. In contrast, 91% of Em-Myc;Mcl-1+/,
83% of Em-Myc;Puma/, and 86% of Em-Myc;Mcl-1+/;
Puma+/ lymphomaswere sIg+ (Figure S2).Western blot analysis
showed that MCL-1 protein levels were lower in several (four out
of seven) Em-Myc;Mcl-1+/;Puma+/ lymphomas than the con-
trol Em-Myc tumors (Figures 4E and S3). This was accompanied
by a slight increase in BCL-XL or BCL-2 and/or a reduction in
pro-apoptotic BIM. However, a substantial fraction (three out
of seven) of the Em-Myc;Mcl-1+/;Puma/ lymphomas had
levels of MCL-1 and BIM similar to Em-Myc lymphomas. The
Em-Myc;Mcl-1+/;Puma/ lymphomas with reduced levels of
MCL-1 tended to have increased levels of BCL-XL and reduced
levels of BIM (Figures 4E and S3). Overall, these results show
that loss of PUMA enhances lymphomagenesis in Em-Myc;Mcl-
1+/ mice only to a relatively minor extent.
Loss of BIM Substantially Accelerates
Lymphomagenesis in Em-Myc;Mcl-1+/ Mice
BIM is a potent antagonist of MCL-1 (Chen et al., 2005; Kuwana
et al., 2005) and functions as a tumor suppressor in several
human cancers (Tagawa et al., 2005; Bachmann et al., 2010;
Richter-Larrea et al., 2010). Accordingly, loss of BIM accelerates
lymphomagenesis in Em-Mycmice and reduces the pressure for
acquisition of p53-pathway defects in these tumors (Egle et al.,
2004). Moreover, BIM is a transcriptional target of MYC (Lee
et al., 2013; Muthalagu et al., 2014). We therefore examined
the role of BIM in the delay of MYC-driven lymphomagenesis
exerted by loss of one Mcl-1 allele.
Consistent with previous findings (Egle et al., 2004; Delbridge
et al., 2015a), Em-Myc mice lacking BIM developed lymphoma
significantly faster than control Em-Myc animals (median survival:
Em-Myc;Bim+/ = 67 days, p < 0.0001 versus Em-Myc; Em-
Myc;Bim/ = 46 days, p < 0.0001 versus Em-Myc). Remarkably,
loss of one or both Bim allele(s) substantially increased
the incidence and accelerated the rate of lymphoma develop-
ment in Em-Myc;Mcl-1+/ mice (median survival: Em-Myc;Mcl-
1+/;Bim+/ = 263 days, Em-Myc;Mcl-1+/;Bim/ = 60.5 days;
p < 0.0001 for both versus Em-Myc;Mcl-1+/; Figure 5A).Reports 14, 2337–2347, March 15, 2016 ª2016 The Authors 2341
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Figure 4. Even Complete Loss of Pro-apoptotic PUMA Accelerates Lymphoma Development in Em-Myc;Mcl-1+/ Mice Only to a Limited
Extent
(A) Kaplan-Meier curves showing lymphoma-free survival of Em-Myc mice of the indicated genotypes (survival curves for Em-Myc and Em-Myc;Mcl-1+/ are
reproduced from Figure 1A for comparison).
(B and C) Leukemic cell counts in the blood (B) and spleenweights (C) of sick Em-Mycmice of the indicated genotypes at sacrifice. In (B) and (C), the color code for
genotypes is the same as in (A), and each symbol represents an individual mouse. Data are presented as mean ± SEM.
(D) Histological analysis of bone marrow (sternum) and spleen specimens of sick mice of the indicated genotypes; representative examples are given. Scale bar
denotes 200 mm.
(E) Western blot analysis of the indicated proteins (HSP70 = loading control) in lymphoma cells from mice of the indicated genotypes (representative of 7–16
lymphomas of each genotype).As previously reported (Egle et al., 2004), sick Em-Myc;Bim+/
and Em-Myc;Bim/ animals had significantly more leukemic
cells in their blood than sick Em-Myc mice (p = 0.0005 and p <
0.0001 versus Em-Myc, respectively; Figure 5B). Despite their
accelerated rate of lymphoma development, sick Em-Myc;Mcl-
1+/;Bim+/ and Em-Myc;Mcl-1+/;Bim/mice had significantly
fewer leukemic cells in their blood than sick Em-Myc;Bim+/ and
Em-Myc;Bim/ mice (p < 0.0001 and p = 0.0003, respectively;
Figure 5B). Furthermore, sick Em-Myc;Mcl-1+/;Bim+/ mice
had significantly lower spleen weights (pspleen = 0.0002) than
sick Em-Myc;Bim+/ mice, but lymph node sizes were similar
(Figures 5B and S5C). Histological analysis showed that lym-
phoma cells were abundant in the bone marrow and spleen (Fig-
ure 5C) and had infiltrated other organs in sick mice of all geno-
types (data not shown). Sick Em-Myc;Mcl-1+/;Bim/ had blood
leukocyte counts comparable to sick Em-Myc;Mcl-1+/ mice
(Figure 5B), but their spleen weights were slightly heavier
(pspleen = 0.047; Figure 5B). Lymphomas from all Em-Myc mice
deficient for one or both Bim alleles were sIg+ (Figure S2).
Western blot analysis showed that Em-Myc;Mcl-1+/;Bim+/
and Em-Myc;Mcl-1+/;Bim/ lymphomas tended to have
MCL-1 levels comparable to control Em-Myc lymphomas, and2342 Cell Reports 14, 2337–2347, March 15, 2016 ª2016 The Authorthe Em-Myc;Mcl-1+/;Bim+/ lymphomas also had similar levels
of BIM, except for one lymphoma in which the p53-pathway
was impaired (#304; Figures 5D and S3). As expected, Em-
Myc;Mcl-1+/;Bim/ lymphomas lacked BIM. Interestingly,
Em-Myc;Mcl-1+/;Bim/ lymphomas with lower levels of MCL-
1 showed a trend toward higher expression of BCL-2 (Figures
5D and S3). These results show that loss of BIM overcomes
the impairment of MYC-driven lymphoma development imposed
by loss of one Mcl-1 allele.
Reduction in BIM Overcomes the Survival Defect
of Pre-leukemic Em-Myc B Cell Progenitors Imposed
by Loss of One Allele ofMcl-1
The observation that loss of BIM greatly accelerates lymphoma-
genesis in Em-Myc;Mcl-1+/ mice suggests that BIM-mediated
apoptosis might be critical for the reduction in pre-leukemic
MYC overexpressing B lymphoid cells that is caused by limiting
MCL-1 levels. To test this hypothesis, we examined the conse-
quences of BIM loss on the pre-leukemic cells in Em-Myc;Mcl-
1+/ mice. FACS sorted pre-leukemic bone-marrow derived
pro-B cells (B220+sIgcKIT+) from Em-Myc;Mcl-1+/;Bim+/
and Em-Myc;Mcl-1+/;Bim/ mice showed significantly betters
survival at 24 hr (p = 0.013 and p = 0.009, respectively), and for
Em-Myc;Mcl-1+/;Bim/ cells also at 48 hr (p = 0.0004), in sim-
ple tissue culture medium compared to their Em-Myc;Mcl-1+/
counterparts (Figure 5E, top). This improved cell survival was re-
flected in significantly increased numbers of pre-leukemic pre-B
cells in the bone marrow of Em-Myc;Mcl-1+/;Bim+/ and
Em-Myc;Mcl-1+/;Bim/ mice compared to Em-Myc;Mcl-1+/
animals, with indeed their numbers rising to the levels seen in
Em-Mycmice and even higher (Figure 5E, bottom). These results
show that loss of BIM (even loss of oneBim allele) overcomes the
survival defect imposed by limiting amounts of MCL-1 in Em-Myc
pre-leukemic B lymphoid progenitors.
DISCUSSION
Overexpression of MCL-1 has been observed in several human
cancers and is implicated in their development as well as resis-
tance to anti-cancer therapeutics (Beroukhim et al., 2010). Here,
we report on the consequences of limited MCL-1 protein levels
on lymphomagenesis. Our studies reveal the importance of
MCL-1 in sustaining the survival of B lymphoid cells undergoing
neoplastic transformation and provide insight into the likely
impact that drugs that inhibit MCL-1 may have on leukemia
and lymphoma cells. Although loss of one Mcl-1 allele did not
noticeably impair the survival of normal B lymphoid cells (i.e.,
in the absence of oncogene activation), it markedly diminished
the survival of MYC overexpressing B cell progenitors. In
contrast, complete loss of BCL-XL kills not only MYC-overex-
pressing B lymphoid cells but also their non-transformed coun-
terparts (Kelly et al., 2011). Remarkably, loss of one Mcl-1 allele
almost completely abrogated lymphoma development in Em-
Myc mice. Similarly, acute loss of a single Mcl-1 allele kills
most malignant Em-Myc lymphomas (Kelly et al., 2014), but not
normal B lymphoid cells (Opferman et al., 2003; Delbridge
et al., 2015b). This demonstrates that deregulated MYC expres-
sion imparts exquisite dependence on MCL-1, but only lesser
dependence on BCL-XL (Kelly et al., 2011, 2014; Delbridge
et al., 2015a) and no dependence on BCL-2 (Kelly et al., 2007).
MYC drives cell growth and proliferation, but this entails repli-
cative stress and DNA lesions that can induce expression of pro-
apoptotic BH3-only proteins (Soucek and Evan, 2010). Hence,
pro-survival signaling is required to sustain the survival of
MYC-overexpressing cells undergoing neoplastic transforma-
tion to allow them to acquire oncogenic lesions that are needed
for full transformation. Until now little was known regarding
which pro-survival BCL-2 family member(s) is/are critical for sur-
vival of nascent neoplastic B cell progenitors to facilitate lympho-
magenesis. Previous studies revealed that BCL-XL (Kelly et al.,
2011; Delbridge et al., 2015a), but not BCL-2 (Kelly et al.,
2007), is critical. MCL-1 is, however, clearly more important
than BCL-XL since loss of one allele of Mcl-1 provided similar
protection as complete loss of BCL-XL (Kelly et al., 2011; Del-
bridge et al., 2015a). Our studies reveal that deregulated MYC
expression renders lymphoma initiating pro-B cells exquisitely
dependent on MCL-1. Why MCL-1 is more important in these
cells than its pro-survival relatives is not clear. The levels of
expression of these pro-survival proteins do not readily provide
an explanation; perhaps the rapid turnover of MCL-1 is neededCellfor the efficient removal of the pro-apoptotic BH3-only proteins
induced by MYC (BCL-2 and BCL-XL proteins have much longer
half-lives).
Loss of BIM (even one allele) substantially accelerates lym-
phomagenesis in Em-Myc;Mcl-1+/ mice, whereas complete
loss of PUMA has much more modest impact. Thus, in MYC-
overexpressing nascent neoplastic lymphoid cells, MCL-1 is
mainly needed to block BIM. In contrast, the defect in emergency
hematopoiesis caused by loss of one Mcl-1 allele is rescued
more potently by loss of PUMA than loss of BIM (Delbridge
et al., 2015b). This differential requirement for distinct BH3-
only proteins for apoptosis induction may indicate cell type spe-
cific differences (i.e., non-transformed hematopoietic stem and
progenitor cells versus nascent neoplastic B cell progenitors)
or differences in the stresses imposed by proliferation induced
by progenitor cell mobilization versus aberrant proliferation
driven by deregulated MYC. MYC can activate Bim transcription
directly by binding to specific sites in its promoter (Lee et al.,
2013; Muthalagu et al., 2014) and indirectly by a still poorly un-
derstood process involving p53 (Happo et al., 2010).
Defects in the p53 pathway are found in 20%–30% of Em-
Myc lymphomas (Eischen et al., 1999; Michalak et al., 2009).
Loss of a single p53 allele greatly accelerated lymphomagenesis
in Em-Myc;Mcl-1+/mice. Indeed, Em-Myc;Mcl-1+/;p53+/mice
have amean survival that is much shorter than that of control Em-
Myc animals. Interestingly, complete loss of PUMA accelerates
lymphomagenesis much less than loss of a single p53 allele.
Thus, the tumor suppressive role of p53 in MYC-induced lym-
phomagenesis must involve processes in addition to PUMA-
mediated apoptosis, perhaps including DNA repair or control
of cellular metabolism (Vousden and Lane, 2007). This is
consistent with the observation that in contrast to loss of
p53, loss of p53-induced apoptosis even in combination
with loss of p53-induced cell-cycle arrest and senescence
(Puma/Noxa/p21/ mice or mice with mutations in p53
that impair transcriptional induction of Puma, Noxa, and p21)
does not cause spontaneous tumor development (Brady et al.,
2011; Li et al., 2012; Valente et al., 2013) and that combined
loss of PUMA and p21 accelerates lymphoma development in
Em-Mycmice to a much lesser extent than loss of one p53 allele
(Valente et al., 2015).
We identified BIM as the critical antagonist of MCL-1 in lym-
phoma development as loss of BIM improved the survival of
pre-leukemic Em-Myc;Mcl-1+/ pro-B cells and massively accel-
erated lymphoma development in Em-Myc;Mcl-1+/ mice. This
extends previous observations that BIM is critical for apoptosis
triggered by deregulatedMYC expression and a potent suppres-
sor of MYC-induced tumorigenesis (Egle et al., 2004; Muthalagu
et al., 2014).
Loss of MCL-1 also delays development of acute myeloid leu-
kemia (AML) driven by several oncogenes (Xiang et al., 2010;
Glaser et al., 2012) and BCR-ABL-driven pre-B leukemia devel-
opment (Koss et al., 2013). Interestingly in these models loss of
both alleles of Mcl-1 was required to delay tumor development.
In the case of BCR-ABL driven pre-B ALL, this may be due to the
fact that this oncogenic kinase promotes BCL-XL expression,
increasing overall pro-survival activity in the lymphoid cells un-
dergoing transformation. In conclusion, MCL-1 is limiting forReports 14, 2337–2347, March 15, 2016 ª2016 The Authors 2343
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the survival of lymphoma initiating cells, particularly those over-
expressing MYC, and development of malignant lymphoma.
Given that non-transformed cells appear to be less dependent
on MCL-1 than malignant cells (Glaser et al., 2012; Kelly et al.,
2014), inhibitors targeting MCL-1 or proteins that promote
MCL-1 expressionmay prove efficacious in the treatment of can-
cer and be tolerable.
EXPERIMENTAL PROCEDURES
Experimental Mice
Experiments with mice were conducted according to the guidelines of the
Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee.
Mcl-1+/ mice were generated from Mcl-1fl mice, described previously (Vik-
strom et al., 2010; Glaser et al., 2012; Kelly et al., 2014), by crossing with
C57BL/6 Cre deleter mice (Schwenk et al., 1995). Bim/ (Bouillet et al.,
1999), Puma/ (Villunger et al., 2003), p53/ (Jacks et al., 1994), and Em-
Mycmice (Adams et al., 1985) have been described previously (all maintained
on a C57BL/6 background for > 20 generations).
Genotyping
Genotyping of mice was performed as previously reported (Grabow et al.,
2014). Primer sequences will be supplied upon request.
Blood Analysis
Peripheral blood samples were taken at the time of sacrifice and analyzed
using an ADVIA blood analyzer (Siemens).
Histological Analysis
Histological analysis was performed as previously reported (Delbridge et al.,
2015b). Scale bars denote 200 mm.
Flow Cytometric Analysis
Single-cell suspensions from tissues were prepared using 100-mM sieves
(BD Biosciences). Cells (5 3 105) were stained for surface markers using
fluorochrome-conjugated (FITC, APC, R-PE; Life Technologies) mono-
clonal antibodies to B220 (RA3-6B2), c-KIT (ACK-2 or ACK-4), IgM (5.1),
and IgD (11-26C; all generated in house) for 30 min in balanced salt solu-
tion (BSS) supplemented with 2% fetal calf serum ([FCS] JHR Biosci-
ences) and 10% normal rat serum and analyzed in a FACS-Calibur (BD
Biosciences).
Immunoblotting
Lysates were prepared in RIPA buffer complemented with COMPLETE
protease inhibitors (Roche). Blots were probed using monoclonal hamster
anti-mouse BCL-2 (3F11; BD Pharmingen), monoclonal mouse anti-
mouse BCL-XL (2F12; BD Pharmingen), monoclonal rat anti-mouse
MCL-1 (19C4-15 [Okamoto et al., 2014]), polyclonal rabbit anti-mouse
PUMA (Ab-27669, Abcam), and polyclonal rabbit anti-mouse BIM (9292;
Sapphire Bioscience) antibodies. Probing with mouse monoclonal anti-Figure 5. Loss of Pro-apoptotic BIM Substantially Increases the In
Em-Myc;Mcl-1+/ Mice
(A) Kaplan-Meier curves showing lymphoma-free survival of Em-Myc mice of th
reproduced from Figure 1A for comparison).
(B) Leukemic cell counts in the blood and spleen weights of sick Em-Mycmice of
same as in (A), and each symbol represents an individual mouse.
(C) Histological analysis of bone marrow (sternum) and spleen specimens from s
bar denotes 200 mm.
(D) Western blot analysis of the indicated proteins (HSP70 = loading control) in
lymphomas of each genotype).
(E) Survival in vitro in simple medium (no added cytokines) of pro-B cells (B220
and 48 hr, as determined by flow cytometry (top). Numbers of pro-B (B220+sIgc
3–4 weeks), as determined by flow cytometric analysis (bottom), are shown. In (B
mean ± SEM. *, **, ***, and **** indicate p values of 0.05, 0.01, 0.001, and < 0.00
CellHSP70 antibody (gift from Dr. R. Anderson, Peter MacCallum Cancer Insti-
tute) was used as a loading control. Polyclonal goat antibodies against
mouse, rat, hamster, or rabbit IgG coupled to HRP (Southern Biotech,
In Vitro Technologies) were used as secondary reagents and enhanced
chemiluminescence ([ECL] GE Healthcare Life Sciences) was used for
detection.
qRT-PCR Analysis
qRT-PCR analysis was conducted as previously described (Grabow et al.,
2012).
DNA Sequence Analysis of the p53 Tumor Suppressor Gene
Exons 4 to 10 of p53 (encoding the DNA binding domain) from 9 Em-Myc;Mcl-
1+/ lymphoma samples were sequenced using the Illumina MiSeq machine
(Illumina) and compared to three normal WT T/B cell samples. All samples
were prepared in technical duplicates using separate subsets of primers. Rep-
licates were prepared on separate plates to ensure reproducibility. For DNA
sequencing all samples were combined into one. Unique primers sets allowed
differentiation between samples and replicates. Dominant reads from each
primer set were aligned using MEGAlign (DNASTAR).
Animal Survival Analysis and Statistical Analysis
Kaplan-Meier survival curves, scatter, and bar graphs for organ weights, blood
parameters, and qRT-PCR were generated and analyzed using the GraphPad
Prism software (GraphPad Software). Mouse cohorts were compared by log-
rank Mantel-Cox test. p values of less than 0.05 were considered to indicate
significant differences. In vitro cell survival data, blood cell counts, and organ
weights were plotted and analyzed with GraphPad Prism using two-tailed
Student’s t test comparing two groups with each other. Data are presented
as mean ± SEM.
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Supplemental Information includes five figures and can be found with this
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